Published online 19 July 2006
© 2006 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.
Survey and Summary |
Defective splicing, disease and therapy: searching for master checkpoints in exon definition
International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano 99 34012 Trieste, Italy
*To whom correspondence should be addressed. Tel: +39 040 3757337; Fax: +39 040 3757361; Email: baralle{at}icgeb.org
Received May 10, 2006. Revised June 27, 2006. Accepted June 28, 2006.
The number of aberrant splicing processes causing human disease is growing exponentially and many recent studies have uncovered some aspects of the unexpectedly complex network of interactions involved in these dysfunctions. As a consequence, our knowledge of the various cis- and trans-acting factors playing a role on both normal and aberrant splicing pathways has been enhanced greatly. However, the resulting information explosion has also uncovered the fact that many splicing systems are not easy to model. In fact we are still unable, with certainty, to predict the outcome of a given genomic variation. Nonetheless, in the midst of all this complexity some hard won lessons have been learned and in this survey we will focus on the importance of the wide sequence context when trying to understand why apparently similar mutations can give rise to different effects. The examples discussed in this summary will highlight the fine ‘balance of power’ that is often present between all the various regulatory elements that define exon boundaries. In the final part, we shall then discuss possible therapeutic targets and strategies to rescue genetic defects of complex splicing systems.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Stucki, T. Suormala, B. Fowler, D. Valle, and M. R. Baumgartner Cryptic Exon Activation by Disruption of Exon Splice Enhancer: NOVEL MECHANISM CAUSING 3-METHYLCROTONYL-CoA CARBOXYLASE DEFICIENCY J. Biol. Chem., October 16, 2009; 284(42): 28953 - 28957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y Habara, Y Takeshima, H Awano, Y Okizuka, Z Zhang, K Saiki, M Yagi, and M Matsuo In vitro splicing analysis showed that availability of a cryptic splice site is not a determinant for alternative splicing patterns caused by +1G->A mutations in introns of the dystrophin gene J. Med. Genet., August 1, 2009; 46(8): 542 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ghosh, H. Kuppusamy, and L. M. Pilarski Aberrant Splice Variants of HAS1 (Hyaluronan Synthase 1) Multimerize with and Modulate Normally Spliced HAS1 Protein: A POTENTIAL MECHANISM PROMOTING HUMAN CANCER J. Biol. Chem., July 10, 2009; 284(28): 18840 - 18850. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sen, I. Talukdar, and N. J. G. Webster SRp20 and CUG-BP1 Modulate Insulin Receptor Exon 11 Alternative Splicing Mol. Cell. Biol., February 1, 2009; 29(3): 871 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Adamia, A. A. Reichert, H. Kuppusamy, J. Kriangkum, A. Ghosh, J. J. Hodges, P. M. Pilarski, S. P. Treon, M. J. Mant, T. Reiman, et al. Inherited and acquired variations in the hyaluronan synthase 1 (HAS1) gene may contribute to disease progression in multiple myeloma and Waldenstrom macroglobulinemia Blood, December 15, 2008; 112(13): 5111 - 5121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Guerra, M. Trerotola, R. Dell' Arciprete, V. Bonasera, B. Palombo, T. El-Sewedy, T. Ciccimarra, C. Crescenzi, F. Lorenzini, C. Rossi, et al. A Bicistronic CYCLIN D1-TROP2 mRNA Chimera Demonstrates a Novel Oncogenic Mechanism in Human Cancer Cancer Res., October 1, 2008; 68(19): 8113 - 8121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Pymar, F. M. Platt, J. M. Askham, E. E. Morrison, and M. A. Knowles Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms Hum. Mol. Genet., July 1, 2008; 17(13): 2006 - 2017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-T. Huang, F.-C. Chen, C.-J. Chen, H.-L. Chen, and T.-J. Chuang Identification and analysis of ancestral hominoid transcriptome inferred from cross-species transcript and processed pseudogene comparisons Genome Res., July 1, 2008; 18(7): 1163 - 1170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Tarrio, F. J. Ayala, and F. Rodriguez-Trelles From the Cover: Alternative splicing: A missing piece in the puzzle of intron gain PNAS, May 20, 2008; 105(20): 7223 - 7228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Parenteau, M. Durand, S. Veronneau, A.-A. Lacombe, G. Morin, V. Guerin, B. Cecez, J. Gervais-Bird, C.-S. Koh, D. Brunelle, et al. Deletion of Many Yeast Introns Reveals a Minority of Genes that Require Splicing for Function Mol. Biol. Cell, May 1, 2008; 19(5): 1932 - 1941. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Habara, M. Doshita, S. Hirozawa, Y. Yokono, M. Yagi, Y. Takeshima, and M. Matsuo A Strong Exonic Splicing Enhancer in Dystrophin Exon 19 Achieve Proper Splicing Without an Upstream Polypyrimidine Tract J. Biochem., March 1, 2008; 143(3): 303 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Klinck, A. Bramard, L. Inkel, G. Dufresne-Martin, J. Gervais-Bird, R. Madden, E. R. Paquet, C. Koh, J. P. Venables, P. Prinos, et al. Multiple Alternative Splicing Markers for Ovarian Cancer Cancer Res., February 1, 2008; 68(3): 657 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Xiao, Z. Wang, M. Jang, and C. B. Burge Coevolutionary networks of splicing cis-regulatory elements PNAS, November 20, 2007; 104(47): 18583 - 18588. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Kralovicova and I. Vorechovsky Global control of aberrant splice-site activation by auxiliary splicing sequences: evidence for a gradient in exon and intron definition Nucleic Acids Res., October 8, 2007; 35(19): 6399 - 6413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Buratti, M. Chivers, J. Kralovicova, M. Romano, M. Baralle, A. R. Krainer, and I. Vorechovsky Aberrant 5' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization Nucleic Acids Res., July 26, 2007; 35(13): 4250 - 4263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Buratti, C. Stuani, G. De Prato, and F. E. Baralle SR protein-mediated inhibition of CFTR exon 9 inclusion: molecular characterization of the intronic splicing silencer Nucleic Acids Res., July 26, 2007; 35(13): 4359 - 4368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Buratti, A. Dhir, M. A. Lewandowska, and F. E. Baralle RNA structure is a key regulatory element in pathological ATM and CFTR pseudoexon inclusion events Nucleic Acids Res., July 26, 2007; 35(13): 4369 - 4383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bhasi, R. V. Pandey, S. P. Utharasamy, and P. Senapathy EuSplice: a unified resource for the analysis of splice signals and alternative splicing in eukaryotic genes Bioinformatics, July 15, 2007; 23(14): 1815 - 1823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Singh, R. N. Singh, and E. J. Androphy Modulating role of RNA structure in alternative splicing of a critical exon in the spinal muscular atrophy genes Nucleic Acids Res., January 28, 2007; 35(2): 371 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Dixon, I. C. Eperon, and N. J. Samani Complementary intron sequence motifs associated with human exon repetition: a role for intragenic, inter-transcript interactions in gene expression Bioinformatics, January 15, 2007; 23(2): 150 - 155. [Abstract] [Full Text] [PDF]
|
|